Clinical trials: sponsored by Fujian Cancer Hospital
Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
This study is a Phase II, two-cohort, multicenter, two-stage clinical trial. It plans to enroll 72 subjects with solid tumors who discontinued prior ICI therapy due to irAE.
- Trial name
- NCT07313202
- Testing
- Ivarmacitinib
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)
Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II
Although multiple immune-checkpoint inhibitors (ICIs) have demonstrated efficacy in recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M-SCCHN), outcomes in the locally advanced (LA-SCCHN) setting remain…
- Trial name
- NCT07310771
- Testing
- Sintilimab combined with chemotherapy and nimotuzumab
- Volunteers
- 23 people
- Sponsor
- Fujian Cancer Hospital
HCC - Hepatocellular Carcinoma
The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer
On the basis of previous studies, this study intends to explore the efficacy of preoperative oral administration of Lactobacillus reuteri (Lr) combined with preoperative neoadjuvant/conversion therapy in patients with primary…
- Trial name
- NCT07306481
- Testing
- Dietary Supplement: L. reuteri DSM 17938
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma by AJCC V9 Stage
Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT07268690
- Testing
- Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma.
- Trial name
- NCT07252375
- Testing
- herombopag olamine tablets
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Small-Cell Carcinoma of the Esophageal
Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal
This study is a prospective, single-center, single-arm phase II clinical trial designed to evaluate the efficacy and safety of serplulimab in combination with etoposide and platinum-based chemotherapy as neoadjuvant treatment for…
- Trial name
- NCT07155122
- Testing
- Drug: Serplulimab, Drug: Etoposide, Drug: Chemotherapy
- Volunteers
- 15 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Cervical Cancer
Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy…
- Trial name
- NICE-CC (NCT07055399)
- Testing
- neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
This prospective, single-center, randomized, controlled, non-inferiority clinical trial aims to compare the safety and postoperative quality of life of early upper gastric cancer patients undergoing total laparoscopic proximal…
- Trial name
- TLPG-CBVP (NCT07142122)
- Testing
- Total laparoscopic proximal gastrectomy with preservation of both the hepatic and celiac branches of the vagus nerve, followed by double-tract reconstruction., Total laparoscopic proximal gastrectomy with preservation of the hepatic branch of the vagus nerve but deliberate resection of the celiac branch, followed by double-tract reconstruction.
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fujian Cancer Hospital
Mid-low Rectal Cancer
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
- Trial name
- NCT06333769
- Testing
- Short-course Radiotherapy, Tislelizumab, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer, Gastric Cancer (GC)
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors
This study is an open-label, non-randomized trial design, including a dose escalation phase and a dose expansion phase, to evaluate the safety, tolerability and preliminary anti-tumor activity of SYS6010 in combination with…
- Conditions
- Colorectal Cancer, Gastric Cancer (GC), Gastrointestinal Tumors
- Trial name
- NCT07104877
- Testing
- SYS6010, SYH2051
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Early Breast Cancer, Adjuvant Therapy
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
This study aims to evaluate the efficacy and safety of adjuvant endocrine therapy combined with dalpiciclib at different doses and durations in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast…
- Conditions
- Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
- Trial name
- NCT07101159
- Testing
- Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Recurrent Nasopharyngeal Carcinoma
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of…
- Trial name
- NCT07088484
- Testing
- ICI-chemotherapy and LIMT
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Esophagus Cancer
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
- Trial name
- NCT07046221
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, cis-platinum
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1
- Trial name
- NCT06793917
- Testing
- Tislelizumab, Oxaliplatin injection, Levo-Leucovorin
- Where
- China
- Volunteers
- 269 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
This is a two-arm, randomized phase II clinical study. It is planned to enroll 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer.
- Trial name
- NCT07070713
- Testing
- FOLFOXIRI + QL1706 + Bevacizumab, FOLFOX+QL1706+Cetuximab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fujian Cancer Hospital
Vunakizumab, Adebrelimab
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
This study is a prospective, single-center, single-arm clinical trial, with a planned enrollment of 28 cases.The first Adebrelimab +Vunakizumab +EC was administered within 72 hours after enrollment for 4 to 6 cycles.At the end of…
- Conditions
- Vunakizumab, Adebrelimab, Small Cell Lung Cancer
- Trial name
- NCT07069270
- Testing
- Vunakizumab (IL-17A inhibitor), Adebrelimab, Chemotherapy
- Volunteers
- 28 people
- Sponsor
- Fujian Cancer Hospital
Cancer Pain
IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
Based on the previous HMORCT09-2, the results show that IV PCA for analgesia maintenance improvements control of severe cancer pain after successful titration.
- Trial name
- NCT04785768
- Testing
- Hydromorphone Hydrochloride Injection, Morphine Sulfate Sustained-release Tablets
- Where
- China
- Volunteers
- 1,372 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Cancer
SLND Versus Non-Dissection Following ESD for T1a Stage Esophageal Squamous Cell Carcinoma
This is a study from Fujian Cancer Hospital Thoracic of Surgery Project, numbered as FJCHTOSP-1. Systematically mediastinal Lymph Node Dissection (SLD) Versus Non-Dissection Following Endoscopic Submucosal Dissection (ESD) for…
- Trial name
- NCT06979986
- Testing
- Endoscopic Submucosal Dissection with Systematically mediastinal Lymph Node Dissection, Endoscopic Submucosal Dissection without SLND
- Volunteers
- 102 people
- Sponsor
- Fujian Cancer Hospital
Immunotherapy, Gastrict Cancer
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.
- Trial name
- NCT05223088
- Testing
- Tislelizumab, Apatinib Mesylate, oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital